StreetInsider.com News Articles

Acadia Healthcare Announces Date for Third Quarter 2026 Earnings Release

Tue, 13 Oct 2026 09:00:00 -0400

FRANKLIN, Tenn.--(BUSINESS WIRE)-- Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that it will release its third quarter 2026 results on Wednesday, November 4, 2026, after the close of the market. Acadia will host a conference call with institutional investors and analysts on Thursday, November 5, 2026 at 9:00 a.m. ET. A live broadcast of the conference call will be available at www.acadiahealthcare.com in the “Investors” section of the website, and the archived webcast will be available after the call has ended.

About Acadia

Acadia is a leading provider of behavioral healthcare services across the

Acadia Healthcare Announces Date for Third Quarter 2026 Earnings Release

Tue, 13 Oct 2026 09:00:00 -0400

About Acadia

Acadia is a leading provider of behavioral healthcare services across the

Form SCHEDULE 13G Acadia Healthcare Compan Filed by: DIMENSIONAL FUND ADVISORS LP

Thu, 08 Oct 2026 14:27:00 -0400

si-local-file:///var/storage/secattach/20261008/27166517.html

Acadia Healthcare (ACHC) Reiterated at Neutral by Cantor Fitzgerald Amid Improving Retention

Tue, 06 Oct 2026 07:30:20 -0400

Cantor Fitzgerald analyst Sarah James reiterated a Neutral rating and $30.00 price target on Acadia Healthcare (NASDAQ: ACHC).

The analyst commented, "We believe the management change prompted an operational change in how jobs are posted, which skews the Q/Q data. Psych openings rose (3.8% vs. 1.3%) and 3/3 bonus metrics worsened, but both have been stable since July, which suggests staffing is unchanged. Management commentary of a stable labor environment, wage growth around 3%, and improving retention supports our assumption that the jumps in opening are operational and not indicative of hiring pressure."

For an analyst ratings summary and ratings history on

RBC Capital on Acadia Pharmaceuticals (ACAD): 'shares remain fundamentally undervalued'

Mon, 05 Oct 2026 13:49:49 -0400

RBC Capital analyst Brian Abrahams reiterated an Outperform rating and a $37.00 price target on Acadia Pharmaceuticals (NASDAQ: ACAD), following a joint stipulation filed by ACAD and generic drugmaker Zydus to dismiss all claims and counterclaims in their pimavanserin (Nuplazid) patent litigation without prejudice.

The dismissal was filed one month before a scheduled November 2 trial, after more than a year of litigation. Zydus had been seeking generic approval for a 34 mg pimavanserin tablet, a formulation distinct from the approved 34 mg capsule. Settlement terms were not disclosed.

Abrahams noted that ACAD still has an outstanding case with Aurobindo/MSN at the

RBC Capital on Acadia Pharmaceuticals (ACAD): 'shares remain fundamentally undervalued'

Mon, 05 Oct 2026 13:49:49 -0400

Abrahams noted that ACAD still has an outstanding case with Aurobindo/MSN at the

RBC Capital on Acadia Pharmaceuticals (ACAD): 'shares remain fundamentally undervalued'

Mon, 05 Oct 2026 13:49:49 -0400

Abrahams noted that ACAD still has an outstanding case with Aurobindo/MSN at the

RBC Capital on Acadia Pharmaceuticals (ACAD): 'shares remain fundamentally undervalued'

Mon, 05 Oct 2026 13:49:49 -0400

Abrahams noted that ACAD still has an outstanding case with Aurobindo/MSN at the

Raymond James Assumes Acadia Healthcare (ACHC) at Outperform

Mon, 28 Sep 2026 07:18:35 -0400

(Updated - September 28, 2026 7:18 AM EDT)

Raymond James analyst Andrew Cooper assumes coverage on Acadia Healthcare (NASDAQ: ACHC) with a Outperform rating and a price target of $39.00.

The analyst comments "We are downgrading Acadia to Outperform from Strong Buy, not on decreased belief in the long-term cash generation potential, but on the likelihood of markets recognizing the value of this potential in our investment horizon. Simply put, questions around the PLGL dynamics will be difficult to address near-term as re-assessment of accruals will not occur again until 4Q. With the 2025 claims experience materially worse ($29M accrual adjustment in

Raymond James Assumes Acadia Healthcare (ACHC) at Outperform

Mon, 28 Sep 2026 07:18:35 -0400

(Updated - September 28, 2026 7:18 AM EDT)

Raymond James analyst Andrew Cooper assumes coverage on Acadia Healthcare (NASDAQ: ACHC) with a Outperform rating and a price target of $39.00.

Raymond James Assumes Acadia Healthcare (ACHC) at Outperform

Mon, 28 Sep 2026 07:18:35 -0400

(Updated - September 28, 2026 7:18 AM EDT)

Raymond James analyst Andrew Cooper assumes coverage on Acadia Healthcare (NASDAQ: ACHC) with a Outperform rating and a price target of $39.00.

Form 8-K Acadia Healthcare Compan For: Sep 25

Fri, 25 Sep 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260925/27107511.html

Form SCHEDULE 13G/A Acadia Healthcare Compan Filed by: Khrom Investments Fund, LP

Fri, 14 Aug 2026 06:35:00 -0400

si-local-file:///var/storage/secattach/20260814/26924252.html

Form SCHEDULE 13G/A Acadia Healthcare Compan Filed by: Khrom Investments Fund, LP

Fri, 14 Aug 2026 06:35:00 -0400

si-local-file:///var/storage/secattach/20260814/26924252.html

Form SCHEDULE 13G/A Acadia Healthcare Compan Filed by: WELLINGTON MANAGEMENT GROUP LLP

Thu, 13 Aug 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260813/26921020.html

Form SCHEDULE 13G/A Acadia Healthcare Compan Filed by: WELLINGTON MANAGEMENT GROUP LLP

Thu, 13 Aug 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260813/26921020.html

Form SCHEDULE 13G/A Acadia Healthcare Compan Filed by: FMR LLC

Thu, 06 Aug 2026 10:15:00 -0400

si-local-file:///var/storage/secattach/20260806/26881003.html

Form SCHEDULE 13G/A Acadia Healthcare Compan Filed by: FMR LLC

Thu, 06 Aug 2026 10:15:00 -0400

si-local-file:///var/storage/secattach/20260806/26881003.html

Acadia Healthcare (ACHC) PT Raised to $39 at Guggenheim

Thu, 30 Jul 2026 07:29:10 -0400

(Updated - July 30, 2026 7:29 AM EDT)

Guggenheim analyst Jason Cassorla raised the price target on Acadia Healthcare (NASDAQ: ACHC) to $39.00 (from $38.00) while maintaining a Buy rating.

The analyst commented: "ACHC reported 2Q26 core EBITDA upside, with strong volumes and solid expense management as the company works through improving ramping bed occupancy. However, the stock fell ~16% (vs S&P 500 -1.5%) in reaction to the print, driven by a combination of heightened buyside expectations and incremental PLGL expenses pressuring what otherwise would have been >500 bps of annualized growth from OOP FL DPP. Despite these dynamics, we assume that

Acadia Healthcare (ACHC) PT Raised to $39 at Guggenheim

Thu, 30 Jul 2026 07:29:10 -0400

(Updated - July 30, 2026 7:29 AM EDT)

Guggenheim analyst Jason Cassorla raised the price target on Acadia Healthcare (NASDAQ: ACHC) to $39.00 (from $38.00) while maintaining a Buy rating.

Acadia Healthcare (ACHC) PT Raised to $32 at Barclays

Thu, 30 Jul 2026 04:57:07 -0400

Barclays analyst Andrew Mok raised the price target on Acadia Healthcare (NASDAQ: ACHC) to $32.00 (from $25.00) while maintaining a Equalweight rating.

Form 8-K Acadia Healthcare Compan For: Jul 28

Tue, 28 Jul 2026 16:57:00 -0400

si-local-file:///var/storage/secattach/20260728/26828143.html

Form 8-K Acadia Healthcare Compan For: Jul 28

Tue, 28 Jul 2026 16:57:00 -0400

si-local-file:///var/storage/secattach/20260728/26828143.html

Form 10-Q Acadia Healthcare Compan For: Jun 30

Tue, 28 Jul 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260728/26827652.html

Form 10-Q Acadia Healthcare Compan For: Jun 30

Tue, 28 Jul 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260728/26827652.html